Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
Sponsor: AJU Pharm Co., Ltd.
Summary
A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately controlled on C52R1L treament
Official title: A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of AJU-C52 in Compared With C52R1M for Essential Hypertension Patients in Inappropriately Controlled on C52R1L Treatment
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
190
Start Date
2022-06-27
Completion Date
2024-08-31
Last Updated
2024-05-22
Healthy Volunteers
No
Conditions
Interventions
AJU-C52L, AJU-C52
AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks. AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks.
C52R1L, C52R1M
C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks. C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks.
Locations (1)
AJU Pharm Co., Ltd.
Seoul, South Korea